EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSMMDG00005014475
Gene Symbol: KCNQ2
1 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSMMDG00005016816
Gene Symbol: KCNQ3
1 Cross references
191 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSMMDG00005005265
Gene Symbol: KCNQ5
1 Cross references
196 Possible Orthologues:

Potassium Voltage-Gated Channel, Kqt-Like Subfamily, Member 2a

Ensembl ID : ENSMMDG00005012154
Gene Symbol: KCNQ2A
1 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel, Shal-Related Subfamily, Member 3

Ensembl ID : ENSMMDG00005015437
Gene Symbol: KCND3
1 Cross references
192 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSMMDG00005016467
Gene Symbol: PSENEN
3 Cross references
183 Possible Orthologues:

Presenilin-2-Like

Ensembl ID : ENSMMDG00005000011
Gene Symbol: LOC115358560
3 Cross references
205 Possible Orthologues:

Primary Amine Oxidase, Liver Isozyme-Like

Ensembl ID : ENSMMDG00005024379
Gene Symbol: LOC115364329
3 Cross references
404 Possible Orthologues:

Primary Amine Oxidase, Liver Isozyme-Like

Ensembl ID : ENSMMDG00005024381
Gene Symbol: LOC115363044
3 Cross references
355 Possible Orthologues:

Probable Histone Deacetylase 1-B

Ensembl ID : ENSMMDG00005020864
Gene Symbol: LOC115354375
3 Cross references
255 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSMMDG00005015606
Gene Symbol: PGR
3 Cross references
193 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSMMDG00005000803
Gene Symbol: PTGDR2
1 Cross references
145 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).